{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-256300","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.256254+00:00","generated_at":"2026-05-17T01:47:37.574866+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Heron Therapeutics appoints Thomas Cusack to board under Rubric Capital agreement","bullets":["Thomas Cusack appointed to Heron's board effective Oct 27, 2025; term expires at 2026 annual meeting.","Cusack was Managing Director at Starboard Value LP (approx. $9B AUM) from 2011-2025.","Appointment made pursuant to Cooperation Agreement with Rubric Capital Management LP dated Aug 8, 2025.","Cusack will serve on the Nominating and Corporate Governance Committee.","Director compensation follows standard non-employee director program described in April 2025 proxy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-256300","json":"https://secwatch.observer/filing/0001193125-25-256300.json","markdown":"https://secwatch.observer/filing/0001193125-25-256300.md","text":"https://secwatch.observer/filing/0001193125-25-256300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312525256300/0001193125-25-256300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312525256300/hrtx-20251027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:47:37.574866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}